Literature DB >> 24558509

ACR Appropriateness Criteria®-Anal Cancer.

Theodore S Hong1, Jennifer L Pretz1, Joseph M Herman2, May Abdel-Wahab3, Nilofer Azad2, A William Blackstock4, Prajnan Das5, Karyn A Goodman6, Salma K Jabbour7, William E Jones8, Andre A Konski9, Albert C Koong10, Miguel Rodriguez-Bigas5, William Small11, Charles R Thomas12, Jennifer Zook13, W Warren Suh14.   

Abstract

The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Although prospective studies point to the use of definitive 5-fluorouracil and mitomycin C-based chemoradiation as a standard, some areas remain that are not well defined. In particular, management of very early stage disease, radiation dose, and the use of intensity-modulated radiation therapy remain unaddressed by phase III studies. The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Entities:  

Keywords:  Anal cancer; Chemoradiation; IMRT; Squamous cell carcinoma; chemotherapy

Year:  2014        PMID: 24558509      PMCID: PMC3924766     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  46 in total

1.  Results of surgical treatment of squamous cell carcinoma of the anal canal and anal margin seen at St. Mark's Hospital 1928-66.

Authors:  J D Hardcastle; H J Bussey
Journal:  Proc R Soc Med       Date:  1968-06

Review 2.  Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.

Authors:  K W Tiver; A O Langlands
Journal:  Aust N Z J Surg       Date:  1984-04

3.  Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.

Authors:  Yuji Seo; Michael T Kinsella; Harry L Reynolds; Gregory Chipman; Scot C Remick; Timothy J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038

4.  Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.

Authors:  B J Cummings; T J Keane; B O'Sullivan; C S Wong; C N Catton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-10       Impact factor: 7.038

5.  A twenty-year experience with adenocarcinoma of the anal canal.

Authors:  George J Chang; Ricardo J Gonzalez; John M Skibber; Cathy Eng; Prajnan Das; Miguel A Rodriguez-Bigas
Journal:  Dis Colon Rectum       Date:  2009-08       Impact factor: 4.585

6.  Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.

Authors:  E Touboul; M Schlienger; L Buffat; D Lefkopoulos; F Pène; R Parc; E Tiret; D Gallot; M Malafosse; A Laugier
Journal:  Cancer       Date:  1994-03-15       Impact factor: 6.860

7.  Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.

Authors:  Andre Konski; Miguel Garcia; Madhu John; Richard Krieg; Wayne Pinover; Robert Myerson; Christopher Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-09       Impact factor: 7.038

8.  US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

10.  Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases.

Authors:  M S Flam; M John; L J Lovalvo; R J Mills; L D Ramalho; C Prather; P A Mowry; D R Morgan; B P Lau
Journal:  Cancer       Date:  1983-04-15       Impact factor: 6.860

View more
  7 in total

Review 1.  Technical aspects of radiation therapy for anal cancer.

Authors:  Eli D Scher; Inaya Ahmed; Ning J Yue; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2014-06

2.  A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients.

Authors:  Michael Buckstein; Yotam Arens; Juan Wisnivesky; Michael Gaisa; Stephen Goldstone; Keith Sigel
Journal:  Dis Colon Rectum       Date:  2018-07       Impact factor: 4.585

Review 3.  Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy.

Authors:  Shanna A Matalon; Harvey J Mamon; Charles S Fuchs; Leona A Doyle; Sree Harsha Tirumani; Nikhil H Ramaiya; Michael H Rosenthal
Journal:  Radiographics       Date:  2015 Nov-Dec       Impact factor: 5.333

Review 4.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Authors:  Rob Glynne-Jones; David Tan; Robert Hughes; Peter Hoskin
Journal:  Nat Rev Clin Oncol       Date:  2016-01-27       Impact factor: 66.675

5.  A population-based analysis of chemoradiation versus radiation alone in the definitive treatment of patients with stage I-II squamous cell carcinoma of the anus.

Authors:  Jacob S Parzen; Aleksander Vayntraub; Bryan Squires; Muayad F Almahariq; Andrew B Thompson; John M Robertson; Peyman Kabolizadeh; Thomas J Quinn
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study.

Authors:  Nadine Houédé; Eric Leutenegger; Mariella Lomma; Carine Bellera
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

7.  Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.

Authors:  Robert Glynne-Jones; David Sebag-Montefiore; Helen M Meadows; David Cunningham; Rubina Begum; Fawzi Adab; Kim Benstead; Robert J Harte; Jill Stewart; Sandy Beare; Allan Hackshaw; Latha Kadalayil
Journal:  Lancet Oncol       Date:  2017-02-11       Impact factor: 41.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.